---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-093791"
form_type: "8-K"
ticker: "ADGM"
cik: "0002006986"
company_name: "Adagio Medical Holdings, Inc."
filed_at: "2026-08-11T12:30:36+00:00"
generated_at: "2026-08-11T12:35:30.296371+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adagio Medical posts Q2 2026 net loss of $6.7M; submits PMA for VT ablation system

## Summary
- Net loss widened to $6.7M ($0.30/share) from $3.9M ($0.26) a year ago; revenue nil.
- R&D spend $2.5M vs $2.0M; SG&A $2.5M vs $2.4M; cash $7.7M at June 30.
- FULCRUM-VT trial (209 pts): 2.4% MAE, 84% freedom from ICD shock, 78% reduced/discontinued antiarrhythmics.
- Submitted PMA to FDA for vCLAS Ventricular Ablation System for monomorphic VT in structural heart disease.
- First patient treated with next-gen vCLAS Ultra catheter under FDA Expanded Access at Penn.

## SEC filing metadata
- accession: 0001104659-26-093791
- form_type: 8-K
- ticker: ADGM
- cik: 0002006986
- company_name: Adagio Medical Holdings, Inc.
- filed_at: 2026-08-11T12:30:36+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006986/000110465926093791/0001104659-26-093791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006986/000110465926093791/tm2622801d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-093791
- JSON: https://secwatch.observer/filing/0001104659-26-093791.json
- Plain text: https://secwatch.observer/filing/0001104659-26-093791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.